Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Manufacturing & supply

Hikma's nationwide US ciprofloxacin tablet recall follows impurity result above FDA guide level

The FDA has logged a Class II, still-open recall of Hikma's US ciprofloxacin tablets, but the entry gives no volumes, so the commercial hit cannot yet be sized.

11 Nov 2026 · FDA enforcement report · Regulator

Hikma Pharmaceuticals USA is recalling ciprofloxacin tablets across the United States, according to the FDA's enforcement report of 11 November 2026. The action is logged as D-0165-2027, classed as Class II, and was still open when the report was published.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official record: FDA enforcement report ↗

Written by CompePharma's editorial system from the official record. AI-assisted; check the source before acting. Not investment advice.

More Manufacturing & supplyAll →